Home › Funds › DAVIS-REA LTD. › ABT
DAVIS-REA LTD. position in ABT
ABBOTT LABORATORIES · Health Care
DAVIS-REA LTD. reported holding 45,021 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$4.4M, representing 1.17% of its reported portfolio and ranking #27 among its reported holdings. DAVIS-REA LTD. has disclosed ABT holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-10-14 · Source: SEC EDGAR Form 13F-HR
How DAVIS-REA LTD.'s ABT position evolved
DAVIS-REA LTD. first disclosed a stake in ABT in Q1 2025 at 38,392 shares (US$5.1M). Across 7 filings, DAVIS-REA LTD. increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 45,021 shares valued at US$4.4M — an increase of 1,519 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 38.39K | $5.09M | New |
| Q2 2025 | 36.74K | $5.00M | Reduce |
| Q3 2025 | 35.89K | $4.81M | Reduce |
| Q4 2025 | 36.50K | $4.57M | Add |
| Q1 2026 | 40.78K | $4.19M | Add |
| Q2 2026 | 43.50K | $3.95M | Add |
| Q3 2026 | 45.02K | $4.45M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on DAVIS-REA LTD.
FAQ
How long has DAVIS-REA LTD. held ABT?
DAVIS-REA LTD. has disclosed ABT holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
What is DAVIS-REA LTD.'s current position in ABT?
As of Q3 2026, DAVIS-REA LTD. holds 45.02K shares of ABT (ABBOTT LABORATORIES), valued at $4.45M, representing 1.17% of its reported portfolio and ranking #27.
Has DAVIS-REA LTD. been buying or selling ABT?
In the latest 13F filing (Q3 2026), DAVIS-REA LTD. increased its position in ABT.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.